Scleroderma in children: emerging management issues.

Area of Science:

• Rheumatology
• Pediatric Autoimmune Diseases
• Dermatology

Background:

• Scleroderma encompasses rare connective tissue diseases characterized by skin thickening and hardening.
• It presents as two main subgroups: systemic (systemic sclerosis) and localized forms.
• Juvenile localized scleroderma is more common, typically affecting specific body areas without internal organ involvement.

Purpose of the Study:

• To review current therapeutic approaches for juvenile localized scleroderma and juvenile systemic sclerosis.
• To highlight the challenges in conducting pediatric clinical trials for rare diseases like scleroderma.
• To emphasize the need for international collaboration in validating scleroderma treatments.

Main Methods:

• Review of existing literature on scleroderma treatment in pediatric populations.
• Extrapolation of therapeutic data from adult scleroderma studies.
• Identification of therapeutic categories for both systemic and localized juvenile scleroderma.

Main Results:

• Therapeutics for juvenile systemic sclerosis include antifibrotics, anti-inflammatories, and vasodilators.
• For localized juvenile scleroderma, treatments investigated include anti-inflammatories, vitamin D analogues, and UV irradiation.
• Randomized controlled trials are challenging due to disease rarity and self-limiting nature in children.

Conclusions:

• Current pediatric scleroderma treatment strategies largely rely on adult data and expert consensus.
• Further research and standardized international protocols are essential for validating existing and novel therapies.
• Emerging treatments like autologous stem cell transplant and cytokine-directed therapies require rigorous investigation.